Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.60
Bid: 3.20
Ask: 4.00
Change: -0.55 (-13.25%)
Spread: 0.80 (25.00%)
Open: 4.15
High: 0.00
Low: 0.00
Prev. Close: 4.15
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

29 Feb 2016 07:00

RNS Number : 3772Q
Proteome Sciences PLC
29 February 2016
 

 

 

 

 

PRESS RELEASE

 

Trading Update

 

 

After closing 2015 with a good increase in revenues in the second half, the current year has started well with a strong order book and a growing pipeline in biomarker services. Following the addition of a further Fusion mass spectrometer in Q4 that doubled the levels of SysQuant®/TMTcalibrator™ production, the increased capacity is being fully utilised in 2016 with four customer projects completed and the volume of customer enquiries rising on a monthly basis. Importantly we are also gaining more repeat business with two significant service contracts signed using SysQuant® and TMTcalibrator™ together totalling £500,000 and with further contracts in discussion. These revenues will fall into the current financial year.

In partnering, we have got off to an active start with prospective licensees for our CK1d compounds to go through the compelling results announced in November for the acute phase study in a different model of Alzheimer's disease that mimicked the effects of the previous chronic study completed in tau. We have been informed that the CE blood test for stroke is on track to be launched by Randox during the year with commensurate milestones payable under the terms of the license. In addition we have the prospect of further non-exclusive licenses to follow. TMT® showed good growth again in 2015 and is expected to continue to increase market share and benefit from the introduction of higher plexing rates in 2016.

We are delighted that the encouraging trends and growth across the business in 2015 have continued into the new year. Proteome Sciences remains firmly on track to deliver a significant increase in revenue from biomarker services and TMT® in 2016 and the possibility of further services contracts and developments in licensing .

 

 

ENDS

 

 

For further information please contact:

 

Proteome Sciences plc

Christopher Pearce, Executive Chairman

Dr. Ian Pike, Chief Operating Officer

Tel: +44 (0)1932 865065

Geoff Ellis, Finance Director

finnCap Limited (nominated adviser & broker)

Geoff Nash/James Thompson

 

Tel : +44 (0)20 7220 0500

Public Relations

IKON Associates

Email: adrian@ikonassociates.com

Adrian Shaw

Tel: +44 (0)1483 271291

Mobile +44(0)7979 900733

 

 

 

 

 

Notes for editors:

 

About Proteome Sciences plc (www.proteomics.com)

With its HQ in Cobham, UK and laboratory facilities in London and Frankfurt, Proteome Sciences is a global leader in applied proteomics offering high sensitivity, proprietary technologies and workflows in cell signalling pathways and in protein biomarker discovery, validation and assay development.

Proteome Sciences' research has discovered a large number of novel protein biomarkers in key human diseases with a focus mainly in neurological/neurodegenerative conditions and in cancer. It has patented blood biomarkers in Alzheimer's disease, stroke, brain damage and cancers for diagnostic and treatment applications that are available for licenses.

PS Biomarker Services® provides proteomics outsourcing services and proprietary biomarker assays from its ISO 9001: 2008 facility in Frankfurt, Germany to pharmaceutical, biotechnology, diagnostics companies and academia.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUNOBRNSAUUAR
Date   Source Headline
15th Sep 20167:00 amRNSHalf-year Report
28th Jul 20167:00 amRNSTrading Update and Notice of Results
24th Jun 201612:30 pmRNSAGM Statement and Result of AGM
1st Jun 20167:00 amRNSAppointment of CEO
31st May 20163:20 pmRNSPublication of Annual Report
18th May 20167:01 amRNSCEO Appointment
18th May 20167:00 amRNSPreliminary Results
5th Apr 20167:00 amRNSDeep Protein Profiling Key re. Cancer Treatment
1st Apr 20168:04 amRNSBlock Admission return
29th Feb 20167:00 amRNSTrading Update
5th Jan 20169:43 amRNSDirector Dealing
14th Dec 20154:02 pmRNSDirector Dealing
14th Dec 20159:36 amRNSHolding(s) in Company
5th Nov 20157:00 amRNSClinical Trial Results for CK1d
1st Oct 20157:00 amRNSBlock Admission return
30th Sep 20157:00 amRNSUnaudited Interim Results
4th Sep 20157:00 amRNSChange of Adviser
17th Jul 201512:01 pmRNSAGM Statement
13th Jul 20152:48 pmRNSHolding(s) in Company
3rd Jul 20155:03 pmRNSHolding(s) in Company
23rd Jun 20157:05 amRNSPublication of Annual Report
23rd Jun 20157:00 amRNSPlacing to raise £2.5 million
29th May 20157:00 amRNSPreliminary results
30th Mar 20154:21 pmRNSBlocklisting Interim Review
9th Mar 20157:00 amRNSTrading Statement
1st Dec 20143:15 pmRNSDirectorate Change
28th Nov 20147:00 amRNSSysQuant - Update/Contract Awards
19th Nov 20145:08 pmRNSHolding(s) in Company
12th Nov 20147:00 amRNSTrading Update
16th Oct 20147:00 amRNSDirectorate Change
1st Oct 20143:54 pmRNSDirector/PDMR Shareholding
30th Sep 20147:01 amRNSBlocklisting Interim Review
30th Sep 20147:00 amRNSDirectorate Change
30th Sep 20147:00 amRNSHalf Yearly Report
26th Sep 20147:00 amRNSCK1d Update: Toxicity Results
25th Sep 201410:08 amRNSContract with Genting TauRx Diagnostic Centre
15th Sep 20147:00 amRNSScience and Technology Award
19th Aug 20147:00 amRNSAppointment of Joint Broker
8th Jul 20145:45 pmRNSDirector/PDMR Shareholding
8th Jul 20147:00 amRNSAlzheimer's blood test study
1st Jul 20147:00 amRNSDirectorate Change
30th Jun 20144:42 pmRNSResult of AGM
9th Jun 20144:18 pmRNSAnnual Financial Report
29th May 20147:00 amRNSPreliminary results
1st Apr 20147:00 amRNSBlocklisting Interim Review
27th Mar 20147:00 amRNSPancreatic Cancer Study in PLOS ONE
3rd Mar 20144:25 pmRNSDirectorate Change
28th Feb 20143:46 pmRNSHolding(s) in Company
24th Feb 20147:00 amRNSPlacing
7th Feb 20147:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.